ArticleJournal of the American Heart Association2023
Intracranial Hemorrhage Rate and Lesion Burden in Patients With Familial Cerebral Cavernous Malformation.
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01764529 (Modifiers of Disease Severity and Progression in Cerebral Cavernous Malformations), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Modifiers of Disease Severity and Progression in Cerebral Cavernous Malformations
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Trial
- Clinical pharmacology and tolerability of REC-994, a redox-cycling nitroxide compound, in randomized phase 1 dose-finding studies.Pharmacology research & perspectives · 2024Trial
- Stroke in a child with cutaneous naevi: a diagnostic trail toward suspected cavernoma-associated phakomatosis with histologic discordance and early multicentric recurrence-adjuvant therapeutic implications.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Leukocytosis at Presentation Is an Independent Predictor for Hemorrhage in Cerebral Cavernoma.Diagnostics (Basel, Switzerland) · 2026Article
- Transient Dysphagia as a Presenting Symptom of Familial Cerebral Cavernous Malformation.Cureus · 2026Article
- Integration of artificial intelligence and high-content screening enabled identification of drugs for long-term treatment of cerebral cavernous malformation disease.bioRxiv : the preprint server for biology · 2025Article
- Familial Cerebral Cavernous Malformations : A Clinical Series and Literature Review.Journal of Korean Neurosurgical Society · 2025Article
- Association of Quality of Life Domains and Clinical Symptoms in Patients With Familial Cerebral Cavernous Malformation.Journal of the American Heart Association · 2025Article
- Unraveling Etiological Indications and Therapeutic Implications of Familial Cerebral Cavernous Malformations in the Dawn of Gene Therapy for Monogenic Conditions.Current gene therapy · 2025Article
- Lifetime Risk of First Symptomatic ICH or Seizure in Familial Cerebral Cavernous Malformations: A Multicenter Patient Data Analysis.Neurology · 2025Article
- Persistent Activation of Endothelial Cells is Linked to Thrombosis and Inflammation in Cerebral Cavernous Malformation Disease.bioRxiv : the preprint server for biology · 2025Article
- Prevalence, genetic and clinical characteristics in first-degree relatives of patients with familial cerebral cavernous malformations in China.Stroke and vascular neurology · 2025Article
- A rare case of unexplained recurrent intracerebral haemorrhage.Journal of surgical case reports · 2025Article
- Current and Future Treatment Options for Cerebral Cavernous Malformations.Stroke (Hoboken, N.J.) · 2024Review
- Circulating biomarkers in familial cerebral cavernous malformation.EBioMedicine · 2024Article
- Article
- Infratentorial Cerebral Cavernous Malformation May be a Risk Factor for Symptomatic Bleeding and Precocity of Symptoms: A Multicenter, Propensity Score Matched, Case-Control Study.Current neurovascular research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
Background Familial cerebral cavernous alformation (CCM) is an autosomal dominant disease caused by mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.